跳至主要内容
临床试验/NCT06489665
NCT06489665招募中不适用

Imaging Quality and Potential Clinical Relevance of Phase Contrast

University of Zurich2 个研究点 分布在 1 个国家目标入组 350 人开始时间: 2024年10月17日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
350
试验地点
2
主要终点
Sensitivity and specificity of PCM compared to FFDM represent the primary outcome since the limited sensitivity of mammography, in particular in patients with dense breasts, represents the major limitation of the currently applied FFDM.

研究概览

简要总结

Conventional mammography, breast sonography and breast MRI have specific weaknesses. In particular, mammography has a low sensitivity for the detection of mammary carcinoma in patients with a dense breast. Phase contrast mammography could help to overcome some of these limitations. Observational study.

详细描述

Category C2 Medicine product without CE label.

Objective(s):

Phase 0: Imaging of mastectomy and breast biopsy samples to validate the image quality and radiation dose. Phase 1: Determination of accurate radiation dose in vivo; dose exposure should remain within the range specified in the investigational brochure. Evaluation of cohort size for phase 2. Phase 2: Assessment of the diagnostic performance of phase contrast mammography compared to conventional digital mammography.

Ouctomes: Sensitivity and specificity of phase contrast mammography compared to conventional digital mammography.

Measurements and procedures:

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Inclusion criteria -Phase 0:
  • >18 years
  • Mastectomy, tumorectomy or biopsy planned
  • Informed consent of the patient
  • Inclusion criteria -Phase 1:
  • >18 years
  • BI-RADS 5 (highly suggestive of malignancy at ultrasound or mammography) or 6 (known biopsy proven malignancy);
  • Scheduled for mastectomy or breast conserving surgery with radiotherapy.
  • Informed consent of the patient
  • Inclusion criteria - Phase 2:
  • >40 years
  • undergoing mammography for screening or diagnostic purpose.
  • Informed consent of the patient

排除标准

  • Exclusion criteria for all three Phases:
  • Breast implants. The women will be asked, if they have a breast-implant.
  • Inability to understand the study procedure due to cognitive or linguistic deficits.
  • Exclusion criteria for patients, participating in Phase 1 and Phase 2:
  • Pregnancy
  • Breast-feeding.
  • Re-staging after neoadjuvant chemotherapy. Patients who participated in prior research projects with ionizing radiation in the past 12 months

结局指标

主要结局

Sensitivity and specificity of PCM compared to FFDM represent the primary outcome since the limited sensitivity of mammography, in particular in patients with dense breasts, represents the major limitation of the currently applied FFDM.

时间窗: 30 month

The standard reference will be the histologic specimen after biopsy

次要结局

  • Lesion extent will be estimated using both PCM and FFDM. Pathological measurements obtained from the surgical specimen will be used as standard of reference.(30 month)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验